Austria · Delayed Price · Currency is EUR Marinomed Biotech AG Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing two late-stage assets, Budesolv and Tacrosolv, with successful clinical results and is in advanced partnering discussions targeting large global markets. Financial restructuring and a recent capital increase support a path to profitability and debt-free status by mid-next year.
-
The company is advancing two late-stage assets, Budesolv and Tacrosolv, targeting large, underserved markets with patented, fast-acting, and preservative-free formulations. Partnering discussions are ongoing globally, with revenue expected from upfront and milestone payments before full regulatory approval.
Fiscal Year 2025
-
The presentation highlighted a proprietary solubilization technology enabling disruptive nasal spray products, a strong financial turnaround through asset sales and debt reduction, and a clear strategy for global market expansion via partnerships. Key product Budesolf is poised for commercialization, with additional pipeline and service revenues supporting growth.